← Leaderboards
Andrew A Wilson
Boston University Medical Campus
$8,485,651
Attributed
$14,664,903
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,664,903 · 8
By mechanism
R01$7,438,827 · 3
U01$4,378,688 · 1
P01$1,866,613 · 2
K08$648,135 · 1
R25$332,640 · 1
Top collaborators
- Yoav Gilad6 shared
- Darrell N. Kotton6 shared
- Edward E Morrisey6 shared
- Chad Albert Cowan5 shared
- Anthony N Hollenberg5 shared
- Anny Xiaobo Zhou3 shared
- Maria Isabel Dominguez2 shared
- Benjamin Alexander Raby1 shared
Most similar at Boston University Medical Campus
Same institution · by research overlap
- Anthony N Hollenberg$16,627,069
- Darrell N. Kotton$37,875,782
- David A Kalman$417,660
- Finn Hawkins$3,451,015
- Konstantinos Alysandratos$1,527,761
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsInduced Pluripotent Stem CellCell TypePhenotypeLung DiseasesPathway InteractionsResearch PersonnelMutationResponseAffectParticipantGenesDisease ModelLungGenome EditingCell LineBiological ModelsProteinsIn VivoFutureIn VitroBasePathogenesisTissues
Grant awards (30)
Mechanistic studies of the genetic contribution of desmoplakin to pulmonary fibrosis in alveolar type 2 cells$776,803
R01 · FY2025 · HL · contact PI
Elucidating the contribution of lung epithelial gain of function toxicity to AATD disease pathogenesis$427,602
P01 · FY2025 · HL · contact PI
iPSC Gene Editing Core$427,602
P01 · FY2025 · HL · contact PI
STaRS at BU - Summer Training as Research Scholars at Boston University$166,320
R25 · FY2025 · HL
Mechanistic studies of the genetic contribution of desmoplakin to pulmonary fibrosis in alveolar type 2 cells$764,263
R01 · FY2024 · HL · contact PI
Elucidating the contribution of lung epithelial gain of function toxicity to AATD disease pathogenesis$584,245
P01 · FY2024 · HL · contact PI
iPSC Gene Editing Core$427,164
P01 · FY2024 · HL · contact PI
STaRS at BU - Summer Training as Research Scholars at Boston University$166,320
R25 · FY2024 · HL
Mechanistic studies of the genetic contribution of desmoplakin to pulmonary fibrosis in alveolar type 2 cells$799,392
R01 · FY2023 · HL · contact PI
Thyroid Hormone Signaling in Human Hepatocytes$336,260
R01 · FY2022 · DK
Thyroid Hormone Signaling in Human Hepatocytes$306,431
R01 · FY2022 · DK
Thyroid Hormone Signaling in Human Hepatocytes$658,627
R01 · FY2021 · DK
A National iPS Cell Network with Deep Phenotyping for Translational Research$799,470
U01 · FY2020 · TR
Thyroid Hormone Signaling in Human Hepatocytes$682,749
R01 · FY2020 · DK
A National iPS Cell Network with Deep Phenotyping for Translational Research$800,405
U01 · FY2019 · TR
Thyroid Hormone Signaling in Human Hepatocytes$695,438
R01 · FY2019 · DK
Personalized therapy for AATD-associated liver disease via IPS modeling$476,963
R01 · FY2019 · DK · contact PI
A National iPS Cell Network with Deep Phenotyping for Translational Research$801,317
U01 · FY2018 · TR
Personalized therapy for AATD-associated liver disease via IPS modeling$476,963
R01 · FY2018 · DK · contact PI
A National iPS Cell Network with Deep Phenotyping for Translational Research$266,475
U01 · FY2018 · TR
A National iPS Cell Network with Deep Phenotyping for Translational Research$805,945
U01 · FY2017 · TR
Personalized therapy for AATD-associated liver disease via IPS modeling$476,963
R01 · FY2017 · DK · contact PI
A National iPS Cell Network with Deep Phenotyping for Translational Research$905,076
U01 · FY2016 · TR
Personalized therapy for AATD-associated liver disease via IPS modeling$484,182
R01 · FY2016 · DK · contact PI
Personalized therapy for AATD-associated liver disease via IPS modeling$503,793
R01 · FY2015 · DK · contact PI
Emphysema attenuation via modulation of macrophage NFKB and antiprotease activity$129,627
K08 · FY2014 · HL · contact PI
Emphysema attenuation via modulation of macrophage NFKB and antiprotease activity$129,627
K08 · FY2013 · HL · contact PI
Emphysema attenuation via modulation of macrophage NFKB and antiprotease activity$129,627
K08 · FY2012 · HL · contact PI
Emphysema attenuation via modulation of macrophage NFKB and antiprotease activity$129,627
K08 · FY2011 · HL · contact PI
Emphysema attenuation via modulation of macrophage NFKB and antiprotease activity$129,627
K08 · FY2010 · HL · contact PI